NXTC · XBRL financial data

NextCure financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NXTC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	22,378	—	—	—	—	—
Research and development	46,554	50,192	54,199	47,931	41,488	44,923
General and administrative	17,049	20,573	21,710	19,706	15,718	12,693
Total operating expenses	63,603	70,765	75,909	67,637	59,748	57,616
Operating income (loss)	(41,225)	(70,765)	(75,909)	(67,637)	(59,748)	(57,616)
Interest expense	183	—	—	—	—	—
Other income (expense)	4,622	1,376	1,176	4,914	4,094	1,772
Income tax expense (benefit)	—	—	—	—	—	0
Net income (loss)	(36,603)	(69,389)	(74,733)	(62,723)	(55,654)	(55,844)
Earnings per share, basic‡ USD per share	(16.63)	(31.38)	(33.63)	(28.13)	(24.88)	(19.65)
Earnings per share, diluted‡ USD per share	(16.63)	(31.38)	(33.63)	(28.13)	(24.88)	(19.65)
Weighted average shares, basic‡ thousands of shares	2,203	2,209	2,220	2,227	2,237	2,842
Weighted average shares, diluted‡ thousands of shares	2,203	2,209	2,220	2,227	2,237	2,842

‡ Per-share figures and share counts are adjusted for the 1-for-12.5 stock split (December 2025); filings made before it reported them unadjusted.

Fiscal years (NXTC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	32,772	12,337	26,630	13,082	27,727	25,982
Marketable securities	250,676	—	—	—	—	—
Prepaid and other current assets	2,824	8,187	4,072	4,426	3,186	1,929
Total current assets	287,978	227,817	163,983	112,725	71,807	43,747
Property and equipment, net	15,809	13,992	11,897	9,033	5,458	3,273
Right-of-use asset	—	—	5,016	4,398	3,263	2,617
Total assets	306,644	242,386	184,161	128,038	80,860	50,183
Accounts payable	3,901	1,942	4,270	2,330	5,353	2,011
Accrued liabilities	4,627	4,449	—	—	—	—
Current portion of long-term debt	1,667	—	—	—	—	—
Total current liabilities	10,325	6,608	9,127	6,883	9,574	10,566
Long-term debt	1,806	—	—	—	—	—
Lease liability, non-current	—	—	6,605	5,949	5,153	4,148
Total liabilities	12,923	9,000	16,631	13,617	15,388	15,240
Accumulated deficit	(117,637)	(187,026)	(261,759)	(324,482)	(380,136)	(435,980)
Total stockholders' equity	293,721	233,386	167,530	114,421	65,472	34,943
Total liabilities and equity	306,644	242,386	184,161	128,038	80,860	50,183
Common shares outstanding (cover page)‡ thousands of shares	2,208	2,218	2,222	2,232	2,241	3,560

‡ Per-share figures and share counts are adjusted for the 1-for-12.5 stock split (December 2025); filings made before it reported them unadjusted.

Fiscal years (NXTC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(36,603)	(69,389)	(74,733)	(62,723)	(55,654)	(55,844)
Stock-based compensation	7,911	10,288	9,508	8,188	6,335	2,986
Depreciation and amortization	3,413	4,300	4,100	3,700	2,900	2,200
Net cash from operating activities	(44,954)	(57,244)	(53,886)	(52,974)	(40,805)	(49,613)
Purchases of property and equipment	7,132	2,360	2,116	820	474	—
Net cash from investing activities	43,523	36,601	67,979	39,272	55,306	25,556
Proceeds from issuing common stock	112	—	—	5	39	—
Net cash from financing activities	(1,415)	(3,265)	200	154	144	22,312
Net change in cash	(2,846)	(23,908)	14,293	(13,548)	14,645	(1,745)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
NextCure	15,260	not reported	(9,715)*	4.6M	1.6 quarters	Q2 FY26 10-QJun 30, 2026
Cellectar Biosciences	33,994	not reported	(6,010)*	9.5M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Synergy CHC	292	5,493	(2,045)	14.9M	0.1 quarters	Q1 FY26 10-QMar 31, 2026
Cypherpunk Technologies	7,624	not reported	(2,692)*	107.8M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026
Cocrystal Pharma	2,169	105	(2,516)*	19.3M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Citius Pharmaceuticals	17,008	1,494	(8,678)*	27.5M	2.0 quarters	Q3 FY26 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.